Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
NCT ID | NCT04285268 |
Title | Rituximab, Venetoclax, and Bortezomib for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma |
Recruitment | Withdrawn |
Gender | both |
Phase | Phase II |
Variant Requirements | No |
Sponsors | Rutgers, The State University of New Jersey |
Indications | |
Therapies | |
Age Groups: | senior | adult |
Covered Countries | USA |
Facility | Status | City | State | Zip | Country | Details |
---|---|---|---|---|---|---|
Rutgers Cancer Institute of New Jersey | New Brunswick | New Jersey | 08903 | United States | Details |